MedPath

Reduction Of Dietary Salt Intake To Control Systolic Blood Pressure In Hypertensive Older Patients

Not Applicable
Not yet recruiting
Conditions
Hypertension
Interventions
Other: educational intervention
Registration Number
NCT05976477
Lead Sponsor
Mario Negri Institute for Pharmacological Research
Brief Summary

REPRESS is an open label, pragmatic, multicenter, randomized controlled phase III trial with blinded endpoint with 1:1 (intervention to control arm) allocation ratio.

The REPRESS trial is aimed to determine the efficacy of an educational intervention aimed at reducing dietary salt intake in elderly people (60+) with moderate hypertension and exposed to polypharmacy (3+ drugs) in improving systolic BP control compared to an attention arm.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
266
Inclusion Criteria
  1. Community-dwelling patients aged ≥60 years;
  2. Prescribed ≥3 drugs;
  3. A) Systolic blood pressure ≥130 and ≤160 mmHg for patients prescribed stable antihypertensive therapy (at least 1 drug (ATC code: C02*, C03*, C07*, C08*, C09*)); B) Systolic blood pressure ≥140 and ≤160 mmHg for those patients not prescribed any antihypertensive drug;
  4. Capable of feeding independently;
  5. Own a smartphone;
  6. Frequently consuming home-cooked meals (≥4 days during a week and ≥3 during the weekend per month);
  7. Giving signed informed consent.
Exclusion Criteria
  1. Living in a nursing home or having applied for nursing home admission;
  2. Being prescribed (adding, switching or changing dosage) an antihypertensive drug in the three months before enrollment;
  3. Undergoing renal replacement therapy with dialysis or having renal impairment with estimated glomerular filtration rate (eGFR) <25 mL/min/1.73 m2 (assessed by CKD-EPI formula) [30] within previous six months or at the screening assessment;
  4. Following a low-sodium dietary regimen;
  5. Being unable or refusing to sign informed consent.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Interventioneducational interventionPatients randomized to intervention arm during the 12 weeks after randomization will receive on their smartphone and/or via e-mail, information materials such as videos, images and recipes for reminders specifically designed to make patients aware on the importance of reducing dietary salt intake and suggestions on how to do it. The educational interventions will be delivered once a week. The main objective of the educational interventions is to spread knowledge about the health risks of excessive salt intake, the actual amount of salt in food, measures to reduce salt intake (e.g. use spices, eat fresh fruits and vegetables, check food labels, gradually reduce the salt in favorite recipes, avoid putting salt and salty sauces on the table, etc.). The interventions, conceived with nutritionists, will be delivered once a week to the participants and to their caregivers and/or the closest family member, involved in the food shopping and the preparation of meals.
Primary Outcome Measures
NameTimeMethod
Change in systolic BP6 months

The primary outcome will be the change in systolic BP defined as the difference from baseline to 12 weeks follow-up in the two study groups.

Secondary Outcome Measures
NameTimeMethod
Change in 24-hour urinary sodium excretion6 and 12 months

The change in the level of 24-hour urinary sodium excretion as the difference from baseline to 12 weeks follow-up (short follow-up), or 6 and 12 months (long follow-up) in the two study arms

Change in adherence to the mediterranean diet6 and 12 months

The change in dietary habits of elderly patients during the 12 months follow-up in the two study groups measured by the adherence to Meditteranean Diet evaluated through the PREDIMED score (higher values correspond to better quality diet)

Incidence of cardio- and cerebro-vascular events12 months

The difference in the incidence of cardio- and cerebro-vascular events during 12-months follow-up between the intervention and the control arm

© Copyright 2025. All Rights Reserved by MedPath